Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Advexin in Oral Premalignancies
NCT00064103Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jun 2003
- Primary completion
- Aug 2007
- Modality
- Gene Editing, Gene Silencing, Viral Vectors
- Countries
- 1
01
Overview
A Phase 2 trial of Ad5CMV-p53 in oral dysplasia (OED), sponsored by National Cancer Institute. Started Jun 2003; status: completed.
02
Drugs
Ad5CMV-p53
03
Conditions
oral dysplasia (OED)
Beyond the preview
Go deeper on NCT00064103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00064103.